Q1 2025 Moderna Inc Earnings Call Transcript
Key Points
- Moderna Inc (MRNA) achieved a 19% reduction in combined cost of sales, R&D, and SG&A expenses compared to the first quarter of 2024, demonstrating strong financial discipline.
- The company ended the quarter with $8.4 billion in cash and investments, providing a solid financial foundation.
- Moderna Inc (MRNA) expanded its market presence with mRESVIA receiving approvals in Australia, Taiwan, the UK, and Switzerland, enhancing its global reach.
- The oncology portfolio was expanded with the Checkpoint program, showing promising early data and aligning with the company's strategy to diversify its pipeline.
- Moderna Inc (MRNA) has a robust late-stage pipeline with multiple regulatory filings and ongoing Phase 3 trials, indicating potential future growth opportunities.
- Moderna Inc (MRNA) reported a net loss of $1 billion for the quarter, reflecting ongoing financial challenges.
- Total revenue for the quarter decreased by 35% year-over-year, highlighting a decline in sales performance.
- The company observed lower vaccination rates compared to the previous year, impacting its COVID vaccine sales.
- The flu COVID combination vaccine's approval timeline has been extended to 2026 due to additional efficacy data requirements, delaying potential revenue from this product.
- The company faces uncertainties in vaccination rates and competitive market environments, which could impact future revenue projections.
Good day and thank you for standing by. Welcome to the Moderna first-quarter 2025 conference call. (Operator Instructions) Please be advised, today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Lavina Talukdar, Head of Investor Relations at Moderna. Please go ahead.
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's first-quarter 2025 financial results and business updates. You can access the press release issued this morning as well as the slides that we will be reviewing by going to the Investors section of our website. On today's call are Stephane Bancel, our Chief Executive Officer; Stephen Hoge, our President; and Jamey Mock, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
